Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27311889 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBMEN1KMT2ALMNA | |
| Benzenemethanethiol SCHEMBL11030198 | 0.89 | POLB (0.66) | SMN1; SMN2POLBMEN1KMT2ALMNA | |
| SCHEMBL1690435 | 0.87 | HPGD (0.68) | SMN1; SMN2POLBMEN1KMT2AHPGD | |
| SCHEMBL10669530 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMEN1KMT2AHPGD | |
| SCHEMBL10596512 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBMEN1KMT2ALMNA | |
| SCHEMBL5247667 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2POLBMEN1KMT2ALMNA | |
| SCHEMBL1186765 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2POLBMEN1KMT2AHPGD | |
| SCHEMBL1696118 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2POLBMEN1KMT2AHPGD | |
| SCHEMBL30608941 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2POLBMEN1KMT2AHPGD | |
| SCHEMBL24447305 | 0.83 | SMN1; SMN2 (0.75) | SMN1; SMN2POLBMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| CN-107428752-A | Home chemokine inhibiting compounds | 癌症研究科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1732893-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | Pfizer Japan, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-7060752-B2 | Synthesis and use of nitrophenol resins | NEW YORK UNIVERSITY (US) | 2006-06-13 | — | — | US | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| EP-1444201-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-20040087726-A1 | Synthesis and use of nitrophenol resins | NEW YORK UNIVERSITY | 2004-05-06 | — | — | US | disclosed |
| WO-2003043981-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | SMN1; SMN2 4322/4885POLB 4667/4885MEN1 1384/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | SMN1; SMN2 4871/4885POLB 2951/4885MEN1 4859/4885 |
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | MCL1, MKI67, MORF4L1 | SMN1; SMN2 10/4885POLB 439/4885MEN1 2331/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SMN1; SMN2 1917/4885POLB 590/4885MEN1 3209/4885 |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 1659/4885POLB 2681/4885MEN1 384/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | SMN1; SMN2 1774/4885POLB 2747/4885MEN1 1064/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | SMN1; SMN2 1774/4885POLB 2747/4885MEN1 1064/4885 |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | SMN1; SMN2 4630/4885POLB 4069/4885MEN1 1713/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | SMN1; SMN2 4322/4885POLB 4667/4885MEN1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.